Anti-tumour effects of elatol, a marine derivative compound obtained from red algae Laurencia microcladia

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 8, 2012, Pages 1146-1154

  Campos, Andreza ^a   Souza, Christiane Borges ^a   Lhullier, Cintia ^a   Falkenberg, Miriam ^a   Schenkel, Eloir Paulo ^a   Ribeiro Do Valle, Rosa Maria ^a   Siqueira, Jarbas Mota ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Apoptosis; B16F10 cells; Cell cycle; Elatol; Laurencia microcladia

Indexed keywords

ALGAL EXTRACT; ANTINEOPLASTIC AGENT; CASPASE 9; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; ELATOL; LAURENCIA MICROCLADIA EXTRACT; PROTEIN BAK; PROTEIN BCL XL; PROTEIN P53; SESQUITERPENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAZIL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LAURENCIA; LAURENCIA MICROCLADIA; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASPASE 9; CELL CYCLE CHECKPOINTS; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; FEMALE; HUMANS; LAURENCIA; MALE; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; SPIRO COMPOUNDS;

EID: 84863721674     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01493.x     Document Type: Article

References (34)

1. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
2. Elliot RL, Blobe GC,. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-2093. (Pubitemid 46211385)
3. Park MT, Lee SJ,. Cell cycle and cancer. J Biochem Mol Biol 2003; 36: 60-65.
4. Stewart ZA, et al,. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24: 139-145. (Pubitemid 36293780)
5. Thompson CB,. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
6. Danial NN, Korsmeyer SJ,. Cell death: critical control points. Cell 2004; 116: 205-219. (Pubitemid 38167313)
7. Sun J, et al,. Sesquiterpenes from the red alga Laurencia tristicha. J Nat Prod 2005; 68: 915-919. (Pubitemid 41017507)
8. Kim MM, et al,. Laurencia okamurai extract containing laurinterol induces apoptosis in melanoma cells. J Med Food 2008; 11: 260-266.
9. Nobili S, et al,. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009; 59: 365-378.
10. Vairappan CS, et al,. Halogenated metabolites with antibacterial activity from the Okinawan Laurencia species. Phytochemistry 2001; 58: 517-523. (Pubitemid 32851740)
11. Kuniyoshi M, et al,. New bromoterpenes from the red alga Laurencia luzonensis. J Nat Prod 2001; 64: 696-700. (Pubitemid 32565912)
12. Brito I, et al,. Oxachamigrenes, new halogenated sesquiterpenes from Laurencia obtusa. J Nat Prod 2002; 65: 946-948. (Pubitemid 34734009)
13. Dos Santos AO, et al,. Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis. Mar Drugs 2010; 8: 2733-2743.
14. Veiga-Santos P, et al,. In vitro anti-trypanosomal activity of elatol isolated from red seaweed Laurencia dendroidea. Parasitology 2010; 137: 1661-1670.
15. Vairappan CS, et al,. Potent antibacterial activity of halogenated metabolites from Malaysian red algae, Laurencia majuscula (Rhodomelaceae, Ceramiales). Biomol Eng 2003; 20: 255-259. (Pubitemid 36959673)
16. Dias T, et al,. Cytotoxic sesquiterpenes from Aplysia dactylomela. J Nat Prod 2005; 68: 1677-1679. (Pubitemid 41789581)
17. Lhullier C, et al,. Isolation of elatol from Laurencia microcladia and its palatability to the sea urchin Echinometra lucunter. Biochem Syst Ecol 2009; 37: 254-259.
18. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63. (Pubitemid 14203433)
19. Bradford M,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
20. Soengas MS, Lowe SW,. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138-3151. (Pubitemid 36713766)
21. Malumbres M, Barbacid M,. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-167.
22. Stein GS, et al,. An architectural perspective off cell-cycle control at the G1/S phase cell-cycle transition. J Cell Physiol 2006; 209: 706-710. (Pubitemid 44665691)
23. Lavhale MS, et al,. A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent. PLoS ONE 2009; 4: e5365.
24. Chari N, et al,. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 2009; 14: 336-347.
25. Stewart ZA, Pietenpol JA,. p53 signaling and cell cycle checkpoints. Chem Res Toxicol 2001; 14: 243-263. (Pubitemid 32238485)
26. Wolff S, et al,. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res 2008; 18: 733-744. (Pubitemid 351948223)
27. Lundberg AS, Weinberg RA,. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35: 1886-1894. (Pubitemid 30026210)
28. Leiter U, et al,. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000; 292: 225-232. (Pubitemid 30265047)
29. Wei MC, et al,. Proapoptotic bax and bak: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730. (Pubitemid 32385543)
30. Cory S, Adams JM,. The bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 9: 647-656. (Pubitemid 37328916)
31. Green DR,. Apoptotic pathways: ten minutes to dead. Cell 2005; 121: 671-674. (Pubitemid 40797590)
32. Helleday T, et al,. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204. (Pubitemid 351301852)
33. Fichtinger-Schepman AM, et al,. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985; 24: 707-713.
34. Huang JC, et al,. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994; 91: 10394-10398.